Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Hellmann

Showing results (71-80 of 172) with videos related to

Pageof 18
Sort By:
Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.
Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.
JCO Precision Oncology|September 11, 2020
Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung AdenocarcinomasMatthew D Hellmann, Takuo Hayashi, Boris Reva, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Pageof 18

Showing results (71-80 of 172) with videos related to

Sort By:
Pageof 18
Cancer Cell|May 8, 2018
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerMatthew D Hellmann, Margaret K Callahan, Mark M Awad, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.
The Lancet. Respiratory Medicine|March 17, 2019
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 studyNatasha B Leighl, Matthew D Hellmann, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.
Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.
Cell|August 10, 2019
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint BlockadeJoseph L Benci, Lexus R Johnson, Ruth Choa, et al.
JCO Precision Oncology|September 11, 2020
Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung AdenocarcinomasMatthew D Hellmann, Takuo Hayashi, Boris Reva, et al.
Nature Medicine|May 1, 2019
Rational design of anti-GITR-based combination immunotherapyRoberta Zappasodi, Cynthia Sirard, Yanyun Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical OutcomesMichael Offin, Joseph M Chan, Megan Tenet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerNaiyer A Rizvi, Matthew D Hellmann, Julie R Brahmer, et al.
Pageof 18